"Bio Farma’s involvement in DCVMN since its establishment is not merely about representation, but about making a tangible contribution toward global vaccine self-reliance," Shadiq said, as noted in a release received here on Tuesday.
Through its participation and innovation, Shadiq emphasized Bio Farma's commitment to providing equitable and sustainable health solutions for all. "We believe that the true strength of the developing countries’ vaccine industry lies in collaboration," he said.
"Through our active role in DCVMN, we aim to ensure that every nation has access to safe, high-quality, and affordable vaccines ... a real manifestation of Indonesia’s contribution to global health security,” he added.
He made the statement ahead of the 26th DCVMN AGM that will be held in Bali on October 29-31, 2025. The meeting is considered an important momentum for Indonesia to reaffirm its role in global health diplomacy.
Through this forum, Bio Farma is committed to advancing innovation, collaboration, and vaccine self-reliance worldwide, toward a more resilient and equitable global health ecosystem.
Since the founding of DCVMN in 2000, Bio Farma has been a driving force in promoting vaccine independence in developing countries. Indonesia's historical role in DCVMN began when the forum was first established.
At the first DCVMN Annual General Meeting (AGM) in Noordwijk in 2000, Bio Farma was one of ten founding members dedicated to advancing vaccine collaboration.
In April 2001, Bio Farma hosted the 2nd AGM in Bandung, where the network formalized the DCVMN’s structure and governance.
Chaired by then-President Director Thamrin Poeloengan, this meeting established Indonesia as a hub for vaccine collaboration and knowledge-sharing among developing countries.
Related news: Bio Farma committed to develop vaccine independence, health resilience
In 2004, Bio Farma, together with other DCVMN members, played a vital role in expanding access to the pentavalent (DPT-HepB-Hib) vaccine through a technology-transfer collaboration with the Netherlands Vaccine Institute.
Global trust in Bio Farma has continued to grow. In 2012, Indonesia once again hosted the 13th DCVMN AGM in Bali. Mahendra Suhardono, one of Bio Farma’s directors at the time, was elected President of the Executive Committee for the 2013 - 2014 term.
Indonesia’s leadership was further recognized when Bio Farma was entrusted to serve as Chair of the Board of DCVMN for the 2023-2025 period, acting as a bridge between network members and global strategic priorities, while showcasing Indonesia’s capacity to lead the vaccine industry in developing countries.
Bio Farma’s commitment to innovation goes far beyond collaboration. In 2020, its nOPV2 vaccine became the first to receive an Emergency Use Listing from the World Health Organization, enabling faster deployment of vaccines during global health emergencies.
This milestone demonstrated that a developing-country manufacturer can achieve world-class innovation, meeting the highest international standards of safety, quality, and efficacy recognized by the WHO.
Beyond being a scientific breakthrough, nOPV2 represents technological self-reliance and global confidence in Indonesia’s capability to contribute meaningfully to international health security.
With a production capacity of more than 3.5 billion doses per year, Bio Farma supplies vaccines to over 150 countries and holds WHO Prequalification certification for 12 types of vaccines.
As the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution, Bio Farma continues to strengthen Indonesia’s strategic role in the global health landscape.
Related news: Bio Farma produces 3.1 million doses for HPV vaccination program
Reporter: Katriana
Editor: Yuni Arisandy Sinaga
Copyright © ANTARA 2025
